Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): A randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604)

被引：4
|
作者：
Reinacher-Schick, A. C.
Kubicka, S.
Freier, W.
Arnold, D.
Dietrich, G.
Geissler, M.
Hegewisch-Becker, S.
Graeven, U.
Schmoll, H.
Schmiegel, W.
机构：
[1] Ruhr Univ Bochum, Bochum, Germany
[2] Leibniz Univ Hannover, Hannover, Germany
[3] Ctr Oncol, Hildesheim, Germany
[4] Univ Halle Wittenberg, Halle, Germany
[5] Bietigheim Hosp, Bietigheim, Germany
[6] Community Hosp, Esslingen, Germany
[7] Ctr Oncol, Hamburg, Germany
[8] Maria Hilf Hosp, Monchengladbach, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.4030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4030
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) versus capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): A randomized phase II study of the AIO GI tumor study group
    Schmiegel, W. H.
    Reinacher-Schick, A.
    Freier, W.
    Dietrich, G.
    Arnold, D.
    Kanzler, S.
    Geissler, M.
    Graeven, U.
    Hegewisch-Becker, S.
    Schmoll, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Sequential first-line treatment for metastatic colorectal cancer with capecitabine, irinotecan, and bevacizumab: Capecitabine plus bevacizumab (Cape-Bev) versus capecitabine, irinotecan plus bevacizumab (CAPIRI-Bev): The AIO KRK 0110/ML22011 randomized, phase III trial
    Giessen, Clemens Albrecht
    Modest, Dominik Paul
    Stintzing, Sebastian
    von Weikersthal, Ludwig Fischer
    Vehling-Kaiser, Ursula
    Spaeth-Schwalbe, Ernst
    Freiberg-Richter, Jens
    Mayerle, Julia
    Bangerter, Markus
    Denzlinger, Claudio
    Sieber, Markus
    Teschendorf, Christian
    Peuser, Bettina
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group
    Schmiegel, W.
    Reinacher-Schick, A.
    Arnold, D.
    Kubicka, S.
    Freier, W.
    Dietrich, G.
    Geissler, M.
    Hegewisch-Becker, S.
    Tannapfel, A.
    Pohl, M.
    Hinke, A.
    Schmoll, H. J.
    Graeven, U.
    ANNALS OF ONCOLOGY, 2013, 24 (06) : 1580 - 1587
  • [4] A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial
    Giessen, Clemens
    von Weikersthal, Ludwig Fischer
    Hinke, Axel
    Stintzing, Sebastian
    Kullmann, Frank
    Vehling-Kaiser, Ursula
    Mayerle, Julia
    Bangerter, Markus
    Denzlinger, Claudio
    Sieber, Markus
    Teschendorf, Christian
    Freiberg-Richter, Jens
    Schulz, Christoph
    Modest, Dominik Paul
    Moosmann, Nicolas
    Aubele, Philipp
    Heinemann, Volker
    BMC CANCER, 2011, 11
  • [5] A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial
    Clemens Giessen
    Ludwig Fischer von Weikersthal
    Axel Hinke
    Sebastian Stintzing
    Frank Kullmann
    Ursula Vehling-Kaiser
    Julia Mayerle
    Markus Bangerter
    Claudio Denzlinger
    Markus Sieber
    Christian Teschendorf
    Jens Freiberg-Richter
    Christoph Schulz
    Dominik Paul Modest
    Nicolas Moosmann
    Philipp Aubele
    Volker Heinemann
    BMC Cancer, 11
  • [6] Phase I/II trial of capecitabine (Cap) and oxaliplatin (Ox) in combination with bevacizumab (Bev) and imatinib (Ima) in patients with metastatic colorectal cancer (CRC): AIO KRK 0205
    von Wichert, G.
    Hoehler, T.
    Schimanski, C. C.
    Moehler, M. H.
    Hofheinz, R.
    Kanzler, S.
    Hinke, A.
    Seufferlein, T.
    Siebler, J.
    Hochhaus, A.
    Arnold, D.
    Hallek, M.
    Hacker, U. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] FOLFOX plus Bevacizumab (Bev) vs. FOLFOXIRI plus Bev in advanced Colorectal Cancer (CRC): A randomized phase II trial (AIO KRK 0209, CHARTA)
    Stein, A.
    Garlipp, B.
    Junghanss, C.
    Leithaeuser, M.
    Vogel, A.
    Schaefers, M.
    Kaiser, U.
    Hoeffkes, H. -G
    Florschuetz, A.
    Ruessel, J.
    Kanzler, S.
    Edelmann, T.
    Forstbauer, H.
    Goehler, T.
    Hannig, C.
    Hildebrandt, B.
    Roll, C.
    Steighardt, J.
    Meinert, F.
    Cygon, F.
    Schmoll, H-J
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 196 - 197
  • [8] Secondary resectability rates observed in a multicenter randomized phase II study of modified capecitabine/ irinotecan (mXELIRI) plus bevacizumab (bev) followed by capecitabine/oxaliplatin (XELOX) plus bev or the reverse sequence in patients with metastatic colorectal cancer (mCRC)
    Scheithauer, W.
    Prager, G.
    Greil, R.
    Mlineritsch, B.
    Schaberl-Moser, R.
    Gerger, A.
    Laengle, F.
    Viragos-Toth, I.
    Andel, J.
    Pichler, A.
    Pecherstorfer, M.
    Kretschmer, A.
    Seebacher, A.
    Jagdt, B.
    Eisterer, W.
    Krippl, P.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Phase II study of the A-ICOX regimen [bevacizumab (Bev), weekly intermittent capecitabine (Cap) and oxaliplatin (Ox)] for untreated advanced colorectal cancer (CRC)
    Ramanathan, R. K.
    Rajasenan, K.
    Crandall, T.
    Balaban, E. P.
    Pinkerton, R. A.
    Kane, P.
    Potter, D. M.
    Dranko, S.
    Schmotzer, A.
    Lembersky, B. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
    Hoehler, T.
    von Wichert, G.
    Schimanski, C.
    Kanzler, S.
    Moehler, M. H.
    Hinke, A.
    Seufferlein, T.
    Siebler, J.
    Hochhaus, A.
    Arnold, D.
    Hallek, M.
    Hofheinz, R.
    Hacker, U. T.
    BRITISH JOURNAL OF CANCER, 2013, 109 (06) : 1408 - 1413
12345